[go: up one dir, main page]

MX2010012860A - Metodos para tratar cancer del sistema nervioso central. - Google Patents

Metodos para tratar cancer del sistema nervioso central.

Info

Publication number
MX2010012860A
MX2010012860A MX2010012860A MX2010012860A MX2010012860A MX 2010012860 A MX2010012860 A MX 2010012860A MX 2010012860 A MX2010012860 A MX 2010012860A MX 2010012860 A MX2010012860 A MX 2010012860A MX 2010012860 A MX2010012860 A MX 2010012860A
Authority
MX
Mexico
Prior art keywords
nervous system
central nervous
methods
treating cancer
subject
Prior art date
Application number
MX2010012860A
Other languages
English (en)
Inventor
I Teichberg Vivian
Ruban-Matuzani Angela
Original Assignee
Yeda Res And Development Co Ltd Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res And Development Co Ltd Star filed Critical Yeda Res And Development Co Ltd Star
Publication of MX2010012860A publication Critical patent/MX2010012860A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01001—Aspartate transaminase (2.6.1.1), i.e. aspartate-aminotransferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01002—Alanine transaminase (2.6.1.2), i.e. alanine-aminotransferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona un método para tratar un cáncer del sistema nervioso central en un sujeto en necesidad del mismo. El método que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un agente que reduce los niveles de glutamato en la sangre y aumenta el efluente de glutamato del cerebro a la sangre para de esta manera tratar el cáncer del sistema nervioso central en el sujeto.
MX2010012860A 2008-05-26 2008-05-26 Metodos para tratar cancer del sistema nervioso central. MX2010012860A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2008/000711 WO2009144699A1 (en) 2008-05-26 2008-05-26 Methods of treating cancer of the central nervous system

Publications (1)

Publication Number Publication Date
MX2010012860A true MX2010012860A (es) 2011-03-02

Family

ID=39639550

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012860A MX2010012860A (es) 2008-05-26 2008-05-26 Metodos para tratar cancer del sistema nervioso central.

Country Status (5)

Country Link
US (3) US9034319B2 (es)
AU (1) AU2008357095B2 (es)
CA (1) CA2725551C (es)
MX (1) MX2010012860A (es)
WO (1) WO2009144699A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2749759C (en) * 2008-01-28 2018-05-15 Milux Holding S.A. An implantable drainage device
MX2010012860A (es) 2008-05-26 2011-03-02 Yeda Res And Development Co Ltd Star Metodos para tratar cancer del sistema nervioso central.
EP2436387B1 (en) 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
US20130023587A1 (en) * 2010-04-01 2013-01-24 Duke University Compositions and methods for the treatment of cancer
CN102298022A (zh) * 2010-06-25 2011-12-28 苏州艾杰生物科技有限公司 甘氨酸的测定方法与甘氨酸测定试剂盒
CN102298023A (zh) * 2010-06-25 2011-12-28 苏州艾杰生物科技有限公司 甘氨酸的测定方法与甘氨酸测定试剂盒
CN102298021A (zh) * 2010-06-25 2011-12-28 苏州艾杰生物科技有限公司 甘氨酸的测定方法与甘氨酸测定试剂盒
CN102298020A (zh) * 2010-06-25 2011-12-28 苏州艾杰生物科技有限公司 甘氨酸的测定方法与甘氨酸测定试剂盒
CA2834535A1 (en) 2011-04-29 2012-11-01 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP3904875B1 (en) 2012-06-29 2024-11-20 Celgene Corporation Methods for determining drug efficacy using ikzf3 (aiolos)
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
TW201536348A (zh) * 2013-07-15 2015-10-01 Alchemia Oncology Pty Ltd 預製備藥物以用於醫療用途的方法
JP6870988B2 (ja) * 2014-02-24 2021-05-19 セルジーン コーポレイション 神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法
ES2843973T3 (es) 2014-06-27 2021-07-21 Celgene Corp Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
WO2017117118A1 (en) 2015-12-28 2017-07-06 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
WO2018229764A1 (en) 2017-06-13 2018-12-20 Yeda Research And Development Co. Ltd. Treatment of advanced or progressive multiple sclerosis
EP3723785A1 (en) * 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
LU100900B1 (de) * 2018-08-10 2020-02-17 Thomas Melchior Homann Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133317A (en) * 1995-11-15 2000-10-17 Hart; Francis J. Oxalic acid or oxalate composition and method of treatment
US6262111B1 (en) * 1997-05-21 2001-07-17 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
CA2457011C (en) * 2001-08-20 2012-04-24 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
EP1524989B1 (en) 2002-08-01 2013-11-06 Yeda Research And Development Co., Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
WO2006066244A2 (en) 2004-12-17 2006-06-22 Cash Alan B Method for extending lifespan and delaying the onset of age-related disease
CA2645678A1 (en) * 2006-03-16 2007-09-20 Yeda Research And Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
EP1925940A1 (en) * 2006-11-23 2008-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Circulating ve-cadherin as a predictive marker of sensitivity or resistance to anti-tumoral treatment, and improved method for the detection of soluble proteins
US20110288070A1 (en) * 2008-05-05 2011-11-24 ROGERS Kathryn Methods for treating cognitive disorders using inhibitors of histone deacetylase
MX2010012860A (es) 2008-05-26 2011-03-02 Yeda Res And Development Co Ltd Star Metodos para tratar cancer del sistema nervioso central.

Also Published As

Publication number Publication date
US20150216949A1 (en) 2015-08-06
US9034319B2 (en) 2015-05-19
AU2008357095B2 (en) 2014-03-13
CA2725551A1 (en) 2009-12-03
US20110070218A1 (en) 2011-03-24
CA2725551C (en) 2017-06-06
AU2008357095A1 (en) 2009-12-03
US10159717B2 (en) 2018-12-25
US20190091300A1 (en) 2019-03-28
WO2009144699A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
MX2010012860A (es) Metodos para tratar cancer del sistema nervioso central.
MX2009011540A (es) Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo.
NZ630367A (en) Methods of treatment of pediatric solid tumor
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
MX2010004074A (es) Combinacion 059.
NZ700759A (en) Combination therapy for treating cancer
GB201016812D0 (en) Method and apparatus for treating respiratory diesease
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
IN2015DN00450A (es)
BRPI0904955A2 (pt) Depósito implantável de drogas para reduzir, prevenir ou tratar dor em um paciente em necessidade de tal tratamento e métodos para tratar dor aguda e para fazer um depósito de drogas implantável.
WO2009155439A3 (en) Use of nitrated lipids for treatment of side effects of toxic medical therapies
MY160406A (en) Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent
EA201491875A1 (ru) Системы и способы лечения индуцированного опиоидами побочного фармакодинамического ответа
ATE538800T1 (de) Kombinationstherapie zur krebsbehandlung
MX2020001727A (es) Terapia de combinacion.
EP2473037A4 (en) METHOD OF TREATING NEURODEGENERATIVE OR DEGENERATIVE NEUROMUSCULAR DISEASES AND THERAPEUTIC AGENT FOR TREATING THESE DISEASES
TN2009000490A1 (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
WO2007134203A3 (en) Anticancer treatments with a combination of docetaxel and ecteinascidin
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2007100590A3 (en) Methods for treating cellulite
MX2007008764A (es) Metodos para tratar capsulitis adhesiva.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
PL1818064T3 (pl) Sposoby traktowania skóry w celu wzmocnienia jej leczenia terapeutycznego

Legal Events

Date Code Title Description
FA Abandonment or withdrawal